The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review

The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review

Nearly 35 million people worldwide live with Alzheimer’s disease (AD). The prevalence of the disease is expected to rise two-fold by 2050. With only symptomatic treatment options available, it is essential to understand the developments and existing evidence that aims to target brain pathology and d...

Full description

Bibliographic Details
Main Authors: Anum Rasheed, Ahmad Bin Zaheer, Aqsa Munawwar, Zouina Sarfraz, Azza Sarfraz, Karla Robles-Velasco, Ivan Cherrez-Ojeda
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Life
Subjects:
CT1812
Elayta
sigma-2
therapeutic candidate
Alzheimer’s disease
clinical trials
Online Access:https://www.mdpi.com/2075-1729/13/1/1

Internet

https://www.mdpi.com/2075-1729/13/1/1

Similar Items